Nurix Therapeutics Inc logo

Nurix Therapeutics Inc(NRIX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$15.48
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NRIX

11/13/2026: NRIX (1-star) is currently NOT-A-BUY. Pass it for now.

Nurix Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target the ubiquitin-proteasome system to treat cancer and inflammatory diseases. Its primary strength lies in its proprietary DELigase platform, which enables the discovery of targeted protein degraders, and its strategic pharmaceutical partnerships that provide essential funding. The investment story centers on the potential for its lead candidates, like NX-5948, to provide therapeutic alternatives in large markets. However, the company carries high clinical development, regulatory, and execution risks, and is not yet profitable. It is most suitable for growth-oriented investors with a high tolerance for volatility who are monitoring clinical trial data.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers high growth potential linked to the advancement of its innovative clinical-stage TPD pipeline.
Momentum investorMixed fitThe stock may see momentum bursts based on positive clinical data readouts.
Value investorWeak fitAs a loss-making biotech, it lacks the earnings metrics required for traditional value analysis.
Dividend investorWeak fitThe company does not pay dividends and focuses all capital on pipeline development.
Low-risk investorWeak fitHigh clinical and regulatory uncertainty makes this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech stocks often experience significant price swings based on clinical trial outcomes.
Valuation riskMedium / highValuations are highly speculative until clinical milestones are achieved.
Competition risk (TPD sector)Medium / highThe protein degradation field is crowded with well-funded competitors.
Business qualityMediumWhile the science is advanced, the company is not yet cash-flow positive.
Dividend incomeLow / noneNo income is returned to shareholders via dividends.
Execution riskHighSuccess depends on the complex execution of clinical trials and regulatory approval.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.69B USD
Price to earnings Ratio 6.42
1Y Target Price 33.5
Price to earnings Ratio 6.42
1Y Target Price 33.5
Volume (30-day avg) 3.5M shares
Beta 1.78
52 Weeks Range 12.43 - 28.23
Updated Date 11/14/2026
52 Weeks Range 12.43 - 28.23
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 2.41

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 15.34%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NRIX receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
NRIX has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+54.0%) is partially offset by negative earnings growth (-36.6%), weak cash generation (FCF margin -313.7%), weak profitability (net margin -314.9%).

Financial Health Rating

★★★★★
NRIX's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 75.6%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is NRIX's strongest growth driver at +54.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-36.6%, negative) and free-cash-flow growth (-44.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 107.9% and approximately 72.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.03% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 8.03%
Vestal Point Capital LP 7.37%
Deep Track Capital, LP 7.08%
Rubric Capital Management LP 6.62%
FMR Inc 5.02%

Unit Economics (Per $1K Revenue)

★★★★★
NRIX generates approximately $775 of gross profit, $-3,402 of operating income, and $-3,137 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.29% (Tax Credit)

Quantitative Style Profile

★★★★★
NRIX has a high-quality, liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedQuality TiltHigh VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Strategic CollaborationsUpfront payments, research funding, and milestone payments from partnerships with large pharmaceutical companies.Revenue is currently driven by the success of research partnerships rather than product sales.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE 6.42
Forward PE -
Enterprise Value 721.37M
Price to Sales(TTM) 2.41
Enterprise Value 721.37M
Price to Sales(TTM) 2.41
Enterprise Value to Revenue 1.03
Enterprise Value to EBITDA 2.36
Shares Outstanding 109.25M
Shares Floating 79.58M
Shares Outstanding 109.25M
Shares Floating 79.58M
Percent Insiders 1.03
Percent Institutions 107.9

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.